Exact Sciences Corporation Overview
Pro stress-test →Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company is best known for developing Cologuard, a non-invasive, stool-based DNA screening test for colorectal cancer that has transformed cancer screening accessibility. The company is currently undergoing acquisition by Abbott Laboratories.
Strategic Profile
Pro stress-test →The company has expanded its portfolio to include Oncotype DX, a suite of genomic tests that analyze tumor biology to guide treatment decisions, and through strategic acquisitions and internal development, has positioned itself as a leader in precision oncology, offering comprehensive cancer screening, diagnosis, and treatment selection solutions. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion.
Competitive Landscape
Pro stress-test →Exact Sciences stands alongside industry leaders like Illumina and Laboratory Corporation with significant revenue and employee base, indicating a competitive environment where offerings like automation, diagnostics, and personalized medicine solutions are crucial for capturing additional market share in cancer detection and research support. Other competitors include Guardant Health, Natera, Veracyte, and Personalis in the molecular diagnostics space.
Industry Context
Exact Sciences Corporation operates in Molecular Diagnostics & Precision Oncology.
Key facts
Founded: 1995 · Headquarters: Madison, Wisconsin · Employees: 6,900 · Revenue: $3.2B · Market cap: $19.7B